Antigen-Binding Protein Complementarity Scoring for Cancer Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for improving adaptive immune responses in cancer treatment are inadequate, and there is a lack of effective approaches for diagnosing and treating cancer patients, particularly in determining the impact of mutant peptides on immune responses.
Innovation Solution
The development of methods to determine complementarity scores between antigen-binding proteins and proteins associated with cancer by isolating nucleic acids, sequencing complementarity determining regions, and calculating scores using net charge per residue and Uversky hydropathy scores to predict overall survival and identify effective antigen-binding proteins for treatment.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current methods for improving adaptive immune responses are used, then some immune therapy approaches are available, but they are inadequate and lack effectiveness in diagnosing and treating cancer patients
Solution Approach 1:
The patent changes the parameter of assessment by introducing complementarity scoring based on electrostatic charge and hydropathy properties. This allows quantitative evaluation of T cell receptor-antigen binding characteristics, transforming the approach from general immune therapy to targeted therapy based on specific molecular complementarity parameters.
Solution Approach 2:
The patent replaces traditional mechanical or empirical methods of assessing immune response with a computational/electrostatic field-based approach. By calculating complementarity scores using electrostatic charge and hydropathy parameters, the method substitutes physical computation for empirical observation, enabling more precise prediction of immune response effectiveness.
2Measurement precision
If complementarity scoring methods are implemented, then prediction of overall survival and identification of effective antigen-binding proteins is enabled, but the complexity of calculating multiple scores (NCPR, Uversky hydropathy) increases
Solution Approach 1:
The patent segments the complementarity assessment into distinct calculable components: electrostatic charge complementarity (NCPR) and hydropathy complementarity (Uversky score). Each component can be calculated independently using established formulas, then combined to give an overall complementarity score. This segmentation makes the complex assessment manageable and computationally efficient.
Solution Approach 2:
The patent introduces complementarity scores as intermediary computational values that mediate between raw sequence data and clinical outcomes. These scores serve as intermediate representations that capture the essential binding characteristics, allowing the system to bridge molecular-level interactions with patient-level prognosis without requiring direct observation of complex biological processes.
3Measurement precision
If sequencing of complementarity determining regions is performed, then specific antigen-binding proteins can be identified, but the cost and time required for nucleic acid isolation and sequencing increases
Solution Approach 1:
The patent performs preliminary computational analysis by calculating complementarity scores from available sequence data before committing to full-scale sequencing or experimental validation. This preliminary scoring can prioritize which samples require detailed sequencing, reducing the overall time and cost by focusing resources on the most promising candidates first.
Data Source
AI summary
The present disclosure relates to methods of determining complementarity scores of antigen-binding proteins and proteins associated with cancers and uses thereof for diagnosing and treating cancers and for screening antigens and antigen-binding proteins.